Results for this period
Full year1 April 2025–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Business revenue resulted from the recognition of milestone revenue from Toray Medical, a contract signing fee from Nipro, and contract research revenue related to an AMED project. The operating loss resulted from the recognition of ¥421.093 million in business expenses, including ¥201.663 million in R&D expenses related to multiple cancer treatments and anti-aging research. The ordinary loss resulted from the recognition of ¥27.009 million in grant income, ¥36.975 million in prize money from the XPRIZE Healthspan competition, and ¥1.326 million in foreign exchange losses, among other items.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥68 million (YoY -48.3%) |
| Operating profit | ¥-356 million |
| Ordinary income | ¥-300 million |
| Profit attributable to owners of the parent | ¥-301 million |
| Net income per share | -¥23.39 |
| Operating Margin | Current fiscal year -520.6 % / Previous period -134.8 % |
| Equity ratio | End of the current fiscal period 94.5 / End of previous period 91.9 |
| Total assets | ¥3,503 million |
| Net assets | ¥3,322 million |
| Cash flows from operating activities | ¥-291 million |
| Cash flows from financing activities | ¥1,894 million |
| Cash and cash equivalents at end of period | ¥3,402 million |
| Full-year earnings forecast | Net Sales ¥43 million (YoY -36.4%) / Operating profit ¥-585 million / Ordinary income ¥-547 million / Net income ¥-548 million |
| Annual Dividend Forecast | ¥0 → ¥0 |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 13,776,900 Shares |
| Treasury Shares at Period-End | 10 Shares |
| Factors Behind Changes in Business Performance | Business revenue resulted from the recognition of milestone revenue from Toray Medical, a contract signing fee from Nipro, and contract research revenue related to an AMED project. The operating loss resulted from the recognition of ¥421.093 million in business expenses, including ¥201.663 million in R&D expenses related to multiple cancer treatments and anti-aging research. The ordinary loss resulted from the recognition of ¥27.009 million in grant income, ¥36.975 million in prize money from the XPRIZE Healthspan competition, and ¥1.326 million in foreign exchange losses, among other items. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Business revenue totaled only ¥68.554 million, despite the recognition of milestone revenue from Toray Medical, a contract signing fee from Nipro, and contract research revenue from an AMED project. The operating loss resulted from the recognition of ¥421.093 million in business expenses, including ¥201.663 million in R&D expenses related to CML, malignant melanoma, non-small cell lung cancer, cutaneous angiosarcoma, pancreatic cancer and anti-aging research. For the next fiscal year, business expenses of ¥627 million are expected, including expenses related to multiple clinical trials and R&D, as well as general and administrative expenses such as personnel costs.